Jean-Pierre Bizzari, MD
Dr. Jean-Pierre (“JP”) Bizzari currently is a member of the Board of Directors of Halozyme, Nordic Nanovector Onexeo, Transgene, and previously of Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals). JP has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Abraxane®, Irinotecan® (CPT-11). As a world-renowned oncology expert, he is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee. Prior to serving as an advisor to emerging biotechnology companies, JP served as EVP and Group Head of Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene (2008-2015). Previously, JP served as VP of Clinical Oncology Development at Sanofi-Aventis (2002-2008), VP of Clinical Oncology at joined Rhône-Poulenc Rorer (1993-2002), and Head of Oncology at Servier (1983-1993). He holds an M.D. specialized in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal McGill Cancer Center in Canada.